Disease-modifying treatment does not influence severity and recovery of the first relapse after treatment onset in RRMS: insights from four large-scale clinical trials
Background: Relapses are the defining clinical feature of relapsing-remitting multiple sclerosis, but it remains uncertain whether disease-modifying treatments influence relapse severity or recovery once a relapse occurs. We investigated whether disease-modifying treatment exposure affects the severity of and recovery from clinical relapses across four pivotal phase 3 relapsing-remitting multiple sclerosis trials. Methods: We used logistic regression models to assess predictors of severe first relapse (Expanded Disability Status Scale worsening > 1.0 point), and Cox proportional hazards models to evaluate factors associated with time to recovery. Predictors included age, sex, disease duration, baseline Expanded Disability Status Scale, T2 lesion volume, contrast-enhancing lesions, relapse severity, corticosteroid treatment and treatment arm. Results: Across all trials, disease-modifying treatments significantly reduced the annualized relapse rate (p < 0.0001) compared to placebo or interferon as an active comparator, but were not associated with relapse severity or recovery time. Relapse recovery followed a similar two-phase course in all trials, with most recovery occurring within 90–120 days. Treatment arm and corticosteroid use were not significantly associated with the time to recovery in any dataset. Conclusions: While disease-modifying treatments reduce relapse frequency, they did not modify relapse severity or recovery once a relapse occurred. These findings suggest that disease-modifying treatments primarily prevent inflammatory events rather than alter their clinical evolution.
Authors
- Jop P. Mostert (ORCID: https://orcid.org/0000-0003-3640-9935)
- Marcus Werner Koch (ORCID: https://orcid.org/0000-0001-9972-5092)
- Pavle Repovic (ORCID: https://orcid.org/0000-0001-7358-6872)
- Øivind Torkildsen (ORCID: https://orcid.org/0000-0001-5294-2866)
- Eva M. M. Strijbis (ORCID: https://orcid.org/0000-0001-6705-5864)
- Tarrant McPherson (ORCID: https://orcid.org/0000-0003-3579-5205)
- Gary Cutter (ORCID: https://orcid.org/0000-0002-8455-980X)
- Miguel D’haeseleer (ORCID: https://orcid.org/0000-0003-4378-0089)
- Jacynthe Comtois (ORCID: https://orcid.org/0000-0002-7748-6104)
- Ester Moral (ORCID: https://orcid.org/0000-0001-6243-9092)
- Luis Brieva
Institutions
- Emory University (US)
- University of Calgary (CA)
- Haukeland University Hospital (NO)
- Hospital Universitari Arnau de Vilanova (ES)
- University of Alabama at Birmingham (US)
- Universitair Ziekenhuis Brussel (BE)
- Hospital de Sant Joan Despí Moisès Broggi (ES)
- Amsterdam University Medical Centers (NL)
- Rijnstate Hospital (NL)
- National MS Center Melsbroek (BE)
- University of Bergen (NO)
- Université de Montréal (CA)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1177/13524585261502632
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00